poisar

Stocks · News reference

Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est

Aug 4, 2026, 8:03 PMBenzinga Newsdesk

Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PCRX
Source
benzinga
Observed
Aug 4, 2026, 8:03 PM
Checked
Aug 4, 2026, 8:03 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 6, 2026, 12:16 PMBenzinga Newsdesk

    Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function

    — A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —— Exploratory clinical outcome measures showed improvements

    Read original at benzinga
    PCRX